Health Catalyst (HCAT) 2026: Earnings Outlook and Strategy
Investors are watching Health Catalyst as healthcare data analytics gain budget priority. This guide breaks down what...
A ten-year comparison of Aristocrats ETFs highlights performance patterns, dividend consistency, and growth trajectory to aid selection.
27,377 articlesInvestors are watching Health Catalyst as healthcare data analytics gain budget priority. This guide breaks down what...
The Council of Multiple Listing Services asks federal antitrust regulators to recognize MLS collaborations as pro-com...
Marvell Technology jumped on news it will join the S&P 500, triggering bullish moves in chips and AI infrastructure p...
Across major firms, AI agents now outnumber human staff in many back offices and customer channels. Leaders outline g...
Palo Alto Networks has surged about a month’s worth of gains, fueling a debate on whether to book profits and rotate ...
On Feb 18, KVUE defied expectations with a stronger quarter, lifting the stock even as the market edged higher. Here’...
Barclays just boosted its Oracle price target to $240, highlighting a sharper focus on Oracle's cloud expansion and A...
Credit conditions are tightening ahead of any Fed move, driven by higher bond yields and a wave of AI financing. Inve...
Halozyme’s halo (HALO) 2026 earnings landscape hinges on ENHANZE collaborations, pipeline milestones, and disciplined...
Private AI valuations are climbing into the hundreds of billions, eclipsing Walmart's public market value and prompti...
Palantir emphasizes software-driven AI workflows with an asset-light model, while Oracle bets on cloud-scale GPU depl...
Hearing aid costs top $7,000 for mid-range devices, and Original Medicare offers no coverage. The gap is reshaping se...